Compare Adaptive Biotechnologies Corp (ADPT) vs Equinix Inc (EQIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Equinix Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while Equinix Inc trades at $1,022.68 (market cap $100.89B). The key difference: Equinix Inc is far larger — about 30.3× Adaptive Biotechnologies Corp's market cap, and Equinix Inc pays a 1.93% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | EQIX | |
|---|---|---|
Market Cap | $3.33B | $100.89B |
Sector | Health | Real Estate |
52-Week High | $22.37 | $1.12K |
52-Week Low | $10.24 | $726.09 |
Enterprise Value | $3.19B | $121.17B |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Equinix (EQIX) trades at $1,022.93, up 2.09% today, with a bearish technical signal despite recent AI partnership news. The stock shows strong revenue growth to $9.22B in 2025 and a net income margin of 15.07%, but faces high valuation multiples (P/E 69.08) and negative net cash flow. Analyst consensus is strongly bullish with a $1,190 price target, though recent earnings misses and elevated debt levels pose concerns.
Outlook remains mixed: AI infrastructure demand offers growth potential, but high leverage and valuation compression risks weigh on near-term upside. Investors should balance strong institutional support against execution risks and macroeconomic headwinds affecting capital-intensive expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
